Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing analytical literature without systematic methodology.
PubMed 24906629 · doi:10.1016/j.jpba.2014.05.020
What was done
The authors reviewed literature published over a 5-year period on analytical approaches for detecting emerging performance-enhancing substances in human blood or urine according to World Anti-Doping Agency regulations. The review categorized and evaluated methods for new drug entities, discontinued pharmaceuticals, and designer compounds across peptidic substances (e.g., modified IGF-1, TB-500, peginesatide, GHRPs, AOD-9604), non-peptidic agents (e.g., SARMs, HIF stabilizers, siRNA, S-107, ARM036/aladorian), and inorganic agents (cobalt), focusing on chromatographic-mass spectrometric and alternative detection methods.
What was found
The abstract reports no quantitative results, assay metrics, limits of detection, or statistical findings. It provides a qualitative narrative detailing how physicochemical properties, in vivo metabolism, and physiological concentration levels govern the selection of chromatographic-mass spectrometric detection strategies for emerging doping agents.
Why it matters
As novel pharmaceutical targets and black-market designer compounds emerge, anti-doping laboratories must continuously adapt analytical protocols to detect diverse low-abundance and structurally distinct substances in biological matrices.
Limits
This is a narrative review with no systematic search protocol, meta-analytic data, or quantitative synthesis. Specific assay performance parameters, detection windows, and comparative method sensitivities are not reported in the abstract.
Cited by
- supports TB-500 is included on the World Anti-Doping Agency (WADA) prohibited list.